ANIVIO
Live / Allowed — Notice of allowance issued (as of 07 Oct 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 11 Sept 2023 filing date already counts against anyone who files later.
Record
- Serial number
- 98173706
- Mark type
- Stylized text
- Filed
- 11 Sept 2023
- Published for opposition
- 12 Aug 2025
- Attorney of record
- Eric R. Moran
Goods and services
- Class 005 — Pharmaceuticals: house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; anti-TNF alpha antibodies for medical purposes; monoclonal antibodies for medical purposes; anti-inflammatories; anti-inflammatory biologic, biosimilar, and pharmaceutical preparations, namely, anti-inflammatory preparations; biologic, biosimilar, and pharmaceutical preparations for the treatment of lung diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of inflammatory disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of pulmonary sarcoidosis; biologic, biosimilar, and pharmaceutical preparations for the treatment of sarcoidosis; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent granulomas; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent fibrosis; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceutical preparations based on human monoclonal antibodies for the treatment of inflammatory diseases and disorders; pharmaceutical preparations containing self-replicating mRNA for the treatment of lung diseases and disorders, inflammatory disorders, pulmonary sarcoidosis, sarcoidosis; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent granulomas; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent fibrosis
- Class 042 — Scientific and technological services: research and development of biologics, biosimilars, pharmaceuticals, and self-replicating mRNA; providing information in the field of scientific and medical research related to biologics, biosimilars, pharmaceuticals, and self-replicating mRNA
- Class 044 — Medical, beauty and agricultural services: providing medical information; providing health information
Owner
- Meitheal Pharmaceuticals, Inc., Chicago, IL, US
- Meitheal Pharmaceuticals, Inc., Chicago, IL, US
Prosecution history
- 07 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 12 Aug 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 12 Aug 2025 — PUBLISHED FOR OPPOSITION
- 06 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 08 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Jun 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 11 Jun 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 11 Jun 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 25 Feb 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 25 Feb 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 11 Dec 2024 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 11 Dec 2024 — FINAL REFUSAL E-MAILED
- 11 Dec 2024 — FINAL REFUSAL WRITTEN
- 06 Nov 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 06 Nov 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE